Bristol-Myers Squibb
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).
Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.
Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.
Top-decile sponsor footprint
Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,025 total, page 12 of 21
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
NCT02032901
To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers
NCT02017730
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
NCT01973049
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
NCT01979939
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
NCT03197779
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968109
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
NCT01986218
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma
NCT02492815
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
NCT01928394
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT01891643
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT01844518
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
NCT01866930
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
NCT01890473
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
NCT01864174
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
NCT01860976
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
NCT01844505
Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
NCT01791491
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
NCT01836705
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects
NCT01858935
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
NCT00996879
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
NCT01837719
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
NCT01741545
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
NCT01820572
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
NCT01752985
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT01795911
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
NCT01775631
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
NCT01766817
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT01714817
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
NCT01707394
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
NCT01718158
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
NCT01766050
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
NCT01660906
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
NCT01750580
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment
NCT01762462
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
NCT01691794
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
NCT01696045
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
NCT01673867
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
NCT01732848
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
NCT01763190
Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
NCT01886599
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
NCT01658878
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
NCT01642004
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
NCT01653470
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
NCT01668784
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
NCT01714739
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 436 |
| Phase 2 | 239 |
| Phase 3 | 213 |
| Phase 4 | 29 |
Therapeutic Areas
What is open in the Bristol-Myers Squibb pipeline
73 recruiting of 1,025 indexed (7% open); 789 completed (77%).
Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).
Top condition: HIV Infections (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bristol-Myers Squibb: open-pipeline peers nationwide
Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,025 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- University of Washington · 1,048 trials · 15% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Bristol-Myers Squibb page
1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.
- 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.